FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065406906> ?p ?o ?g. }

• W2065406906 endingPage "1452" @default.
• W2065406906 startingPage "1442" @default.
• W2065406906 abstract "In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML).Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m(2) as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events.Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as < or = 5% blasts in the bone marrow without leukemic blasts in the peripheral blood, neutrophil recovery to > or = 1500/microL, hemoglobin > or = 9 g/dL, and independence from red blood cell and platelet transfusions. Complete remission (CR) with platelet recovery (> or = 100,000/microL) or without full platelet recovery (< 100,000/microL) (CRp) was observed in 35 patients (13%) and 36 patients (13%), respectively. The median recurrence-free survival was 6.4 months for patients who achieved CR and 4.5 months for patients who achieved CRp. Although expected incidences of Grade 3 or 4 neutropenia (98%) and thrombocytopenia (99%) were observed, the incidence of Grade 3 or 4 sepsis (17%) and pneumonia (8%) was relatively low. Grade 3 or 4 hyperbilirubinemia and hepatic aspartate aminotransferase and alanine aminotransferase elevations were reported in 29%, 18%, and 9% of patients, respectively; 0.9% of patients who did not undergo prior or subsequent hematopoietic stem cell transplantation developed hepatic venoocclusive disease after GO treatment.When it was administered to patients with CD33-positive AML in first recurrence, single-agent GO induced a 26% remission rate with a generally acceptable safety profile." @default.
• W2065406906 created "2016-06-24" @default.
• W2065406906 creator A5000436961 @default.
• W2065406906 creator A5005303780 @default.
• W2065406906 creator A5006790084 @default.
• W2065406906 creator A5021879267 @default.
• W2065406906 creator A5029801761 @default.
• W2065406906 creator A5031662456 @default.
• W2065406906 creator A5035535476 @default.
• W2065406906 creator A5044077859 @default.
• W2065406906 creator A5046775582 @default.
• W2065406906 creator A5050992845 @default.
• W2065406906 creator A5056405520 @default.
• W2065406906 creator A5056450428 @default.
• W2065406906 creator A5057920623 @default.
• W2065406906 creator A5063746286 @default.
• W2065406906 creator A5065804627 @default.
• W2065406906 creator A5084012303 @default.
• W2065406906 creator A5089969677 @default.
• W2065406906 date "2005-10-01" @default.
• W2065406906 modified "2023-10-03" @default.
• W2065406906 title "Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence" @default.
• W2065406906 cites W1492445977 @default.
• W2065406906 cites W1519562949 @default.
• W2065406906 cites W1685882185 @default.
• W2065406906 cites W1709114039 @default.
• W2065406906 cites W183128447 @default.
• W2065406906 cites W1842764967 @default.
• W2065406906 cites W1861929829 @default.
• W2065406906 cites W1970204399 @default.
• W2065406906 cites W1972529152 @default.
• W2065406906 cites W1973018895 @default.
• W2065406906 cites W1979969603 @default.
• W2065406906 cites W1993078113 @default.
• W2065406906 cites W1995697319 @default.
• W2065406906 cites W1996264890 @default.
• W2065406906 cites W1997142601 @default.
• W2065406906 cites W2000838340 @default.
• W2065406906 cites W2066559306 @default.
• W2065406906 cites W2076106584 @default.
• W2065406906 cites W2077248326 @default.
• W2065406906 cites W2138388661 @default.
• W2065406906 cites W2160480581 @default.
• W2065406906 cites W2160835020 @default.
• W2065406906 cites W2331244012 @default.
• W2065406906 cites W2764775166 @default.
• W2065406906 cites W3082443879 @default.
• W2065406906 cites W4312790597 @default.
• W2065406906 doi "https://doi.org/10.1002/cncr.21326" @default.
• W2065406906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16116598" @default.
• W2065406906 hasPublicationYear "2005" @default.
• W2065406906 type Work @default.
• W2065406906 sameAs 2065406906 @default.
• W2065406906 citedByCount "410" @default.
• W2065406906 countsByYear W20654069062012 @default.
• W2065406906 countsByYear W20654069062013 @default.
• W2065406906 countsByYear W20654069062014 @default.
• W2065406906 countsByYear W20654069062015 @default.
• W2065406906 countsByYear W20654069062016 @default.
• W2065406906 countsByYear W20654069062017 @default.
• W2065406906 countsByYear W20654069062018 @default.
• W2065406906 countsByYear W20654069062019 @default.
• W2065406906 countsByYear W20654069062020 @default.
• W2065406906 countsByYear W20654069062021 @default.
• W2065406906 countsByYear W20654069062022 @default.
• W2065406906 countsByYear W20654069062023 @default.
• W2065406906 crossrefType "journal-article" @default.
• W2065406906 hasAuthorship W2065406906A5000436961 @default.
• W2065406906 hasAuthorship W2065406906A5005303780 @default.
• W2065406906 hasAuthorship W2065406906A5006790084 @default.
• W2065406906 hasAuthorship W2065406906A5021879267 @default.
• W2065406906 hasAuthorship W2065406906A5029801761 @default.
• W2065406906 hasAuthorship W2065406906A5031662456 @default.
• W2065406906 hasAuthorship W2065406906A5035535476 @default.
• W2065406906 hasAuthorship W2065406906A5044077859 @default.
• W2065406906 hasAuthorship W2065406906A5046775582 @default.
• W2065406906 hasAuthorship W2065406906A5050992845 @default.
• W2065406906 hasAuthorship W2065406906A5056405520 @default.
• W2065406906 hasAuthorship W2065406906A5056450428 @default.
• W2065406906 hasAuthorship W2065406906A5057920623 @default.
• W2065406906 hasAuthorship W2065406906A5063746286 @default.
• W2065406906 hasAuthorship W2065406906A5065804627 @default.
• W2065406906 hasAuthorship W2065406906A5084012303 @default.
• W2065406906 hasAuthorship W2065406906A5089969677 @default.
• W2065406906 hasConcept C10205521 @default.
• W2065406906 hasConcept C126322002 @default.
• W2065406906 hasConcept C141071460 @default.
• W2065406906 hasConcept C176290653 @default.
• W2065406906 hasConcept C197934379 @default.
• W2065406906 hasConcept C2776694085 @default.
• W2065406906 hasConcept C2777063308 @default.
• W2065406906 hasConcept C2777408962 @default.
• W2065406906 hasConcept C2778245361 @default.
• W2065406906 hasConcept C2778623314 @default.
• W2065406906 hasConcept C2778729363 @default.
• W2065406906 hasConcept C28328180 @default.
• W2065406906 hasConcept C2911091166 @default.
• W2065406906 hasConcept C54355233 @default.

• next